|Title:||Twelve-dose weekly rifapentine plus isoniazid for latent tuberculosis infection: A multicentre randomised controlled trial in Taiwan||Authors:||LIH-YU CHANG||Issue Date:||2018||Journal Volume:||111||Start page/Pages:||121-126||Source:||Tuberculosis||Abstract:||
Treatment of latent tuberculosis (TB) infection (LTBI) effectively prevents its progression to active TB. However, long treatment duration and drug-related hepatotoxicity limit the effectiveness of the 9-month daily isoniazid (9H). Data on the 3-month weekly rifapentine plus isoniazid (3 HP) in Asian populations are currently unavailable. We prospectively randomised the LTBI contacts aged ?12 years with positive tuberculin skin test into 9H and 3 HP groups in four hospitals between January 2014 and May 2016 in Taiwan. The primary and secondary outcomes were treatment completion rate and adverse drug reactions (ADRs), respectively. Overall, 263 participants with LTBI were randomised into the 3 HP (n = 132) and 9H groups (n = 131); 14 (10.6%) and 29 (22.1%) participants in the 3 HP and 9H groups, respectively, discontinued therapy (p = 0.011). Discontinuation rates owing to ADRs were 9.1% (3 HP) and 5.3% (9H) (p = 0.241). Clinically relevant hepatotoxicity was more common in the 9H than in the 3 HP group (5.3% vs. 1.5%; p = 0.103), whereas systemic drug reaction was more common in the 3 HP than in the 9H group (3.8% vs. 0%; p = 0.060). Women had a significantly higher rate of Grade II fever than men (13.7% vs. 1.2%; p = 0.003). Compared with the 9H regimen, the 3 HP regimen had a higher completion rate with lower hepatotoxicity and well-tolerated ADR. Clinical trials registration: number NCT02208427. ? 2018 The Authors
|DOI:||10.1016/j.tube.2018.05.013||metadata.dc.subject.other:||isoniazid; rifapentine; isoniazid; rifampicin; rifapentine; tuberculostatic agent; abdominal pain; adult; Article; Asian; blurred vision; bronchospasm; chill; controlled study; diarrhea; dizziness; drug withdrawal; dyspnea; fatigue; female; fever; flu like syndrome; headache; heart palpitation; hepatitis; hot flush; human; hypersomnia; hypotension; latent tuberculosis; liver toxicity; major clinical study; male; menstrual irregularity; multicenter study; myalgia; nausea; ocular pruritus; open study; priority journal; prospective study; randomized controlled trial; rash; skin manifestation; Taiwan; tuberculin test; unspecified side effect; vomiting; xerostomia; adolescent; aged; analogs and derivatives; child; clinical trial; combination drug therapy; comparative study; drug effect; latent tuberculosis; microbiology; middle aged; Mycobacterium tuberculosis; pathogenicity; time factor; treatment outcome; young adult; Adolescent; Adult; Aged; Antibiotics, Antitubercular; Antitubercular Agents; Child; Drug Therapy, Combination; Female; Humans; Isoniazid; Latent Tuberculosis; Male; Middle Aged; Mycobacterium tuberculosis; Prospective Studies; Rifampin; Taiwan; Time Factors; Treatment Outcome; Young Adult
|Appears in Collections:||醫學院附設醫院 (臺大醫院)|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.